정규장
Log in Sign up
SXTP
SXTP
60 Degrees Pharmaceuticals Inc
7월 28일 1:00 PM ET (한국 7/29 02:00)
$1.57
+0.09 ▲ +6.08%

식스티 디그리즈 파마슈티컬스(SXTP) is a Healthcare sector company, analyzed across 14 metrics on this page including P/E, EPS, dividends, RSI, and MACD.

시황 · 실적발표 · 매수매도 신호, 가장 먼저 받아보세요 🔔 구독
시가총액
$4M
스몰캡
P/E
-
배당수익률
없음
52주 위치
5%
저점 +29% · 고점 -82%
애널리스트
매수
C+
Fundamental health
vs. 초고성장주 초소형주· based on 2 axes
수익성 ⓘ
산출 불가 (적자)
성장 ⓘ
Top 46%
밸류에이션 ⓘ
데이터 부족
재무 안정 ⓘ
Top 51%
Index ⓘ -P/E ⓘ -EPS (ttm) ⓘ -10.29Insider Own ⓘ 0.88%Shs Outstand ⓘ 2.6MPerf Week ⓘ 3.97%
Market Cap ⓘ 0.00BForward P/E ⓘ -EPS next Y ⓘ 35.05%Insider Trans ⓘ 45.72%Shs Float ⓘ 2.6MPerf Month ⓘ -4.27%
Enterprise Value ⓘ 0.01BPEG ⓘ -EPS next Q ⓘ -0.73Inst Own ⓘ 7.31%Short Float ⓘ 5.55%Perf Quarter ⓘ -3.68%
Income ⓘ -0.01BP/S ⓘ 3.19EPS this Y ⓘ 71.91%Inst Trans ⓘ 8.35%Short Ratio ⓘ 1.69Perf Half Y ⓘ -65.42%
Sales ⓘ 0.00BP/B ⓘ -EPS next 5Y ⓘ 62.88%ROA ⓘ -118.59%Short Interest ⓘ 0.15MPerf YTD ⓘ -22.78%
Book/sh ⓘ -1.8P/C ⓘ 1.25EPS past 3/5Y ⓘ 64.19% 37.74%ROE ⓘ -169.02%52W High ⓘ -81.79% ($8.62)Perf Year ⓘ -70.04%
Cash/sh ⓘ 1.25P/FCF ⓘ -Sales past 3/5Y ⓘ 40.21% -11.18%ROIC ⓘ -151.94%52W Low ⓘ 28.69% ($1.22)Perf 3Y ⓘ -99.7%
Dividend Est. ⓘ -EV/EBITDA ⓘ -EPS Y/Y TTM ⓘ 91.75%Gross Margin ⓘ 39.6%Volatility(W/M) ⓘ 7.6% 8.26%Perf 5Y ⓘ -
Dividend TTM ⓘ -EV/Sales ⓘ 8Sales Y/Y TTM ⓘ 66.12%Oper. Margin ⓘ -604.05%ATR (14) ⓘ 0.13Perf 10Y ⓘ -
Dividend Ex-Date ⓘ -Quick Ratio ⓘ 2.85EPS Q/Q ⓘ 79.52%Profit Margin ⓘ -613.21%RSI (14) ⓘ 51.4Recom ⓘ 2
Dividend Gr. 3/5Y ⓘ -Current Ratio ⓘ 3.34Sales Q/Q ⓘ -36.75%SMA20 ⓘ -0.73% ($1.58)Beta ⓘ 2.48Target Price ⓘ $3.7
Payout ⓘ -Debt/Eq ⓘ 0.03Earnings ⓘ 2026/05/14SMA50 ⓘ 2.78% ($1.53)Rel Volume ⓘ 0.94Prev Close ⓘ $1.48
Employees ⓘ 5LT Debt/Eq ⓘ 0.03EPS/Sales Surpr. ⓘ -68.42% -47.13%SMA200 ⓘ -44.76% ($2.84)Avg Volume(3M) ⓘ 0.09MPrice ⓘ $1.57
IPO ⓘ 2023/7/12Option/Short ⓘ No/YesTrades ⓘ 337Volume ⓘ 81,260Change ⓘ 6.08%
Quarterly earnings trend SEC filings · USD
24.6
24.9
24.12*
25.3
25.6
25.9
25.12*
26.3
Revenue Net income 최근 분기: 매출 $0M (YoY -1%) · 순이익 $-2M (YoY -11%)
* Q4 figures are derived from the annual filing (10-K) · loss-making quarters are underlined in red

📊 60 Degrees Pharmaceuticals Inc (SXTP) Investment Analysis

What kind of company is 60 Degrees Pharmaceuticals Inc?

식스티 디그리즈 파마슈티컬스(SXTP) 초고성장주
Healthcare · Biotechnology
Small-Cap — Low Volume, High Volatility

💊 60 Degrees Pharmaceuticals () is a specialty pharmaceutical company headquartered in Washington, D.C., focused on the prevention and treatment of infectious diseases. Its flagship product is Arakoda (tafenoquine), a malaria prevention drug. Although its revenue is very small, it is a micro-cap stock pursuing a strategy of boosting margins through a cash-pay model.

Learn more about 60 Degrees Pharmaceuticals Inc →
Market Cap
$0.0B
Approx. KRW 0.0 trillion
⚖️ 0% of Samsung Electronics
Market Cap Rank5711
Employees5people
IPO2023/07/12
Current Price$1.57 ≈ 2,151원
NASD · USA

Key Events

⏰ Upcoming events
🔔 Earnings release
The next release date has not been announced yet.
🎯 Ex-dividend date
No scheduled dividends
📜 Recent events
🔔 Earnings release 2026년 5월 14일 (목) · 장 마감 후 EPS -68.4% 매출 -47.1%
🔔 Earnings release 2026년 3월 30일 (월) · 장 마감 후 EPS -15.0% 매출 -3.1%

Is it profitable?

Financially sound but profitability is low
Losses or thin margins — early-stage growth or weakening competitiveness
Profitability — How efficiently it makes money
Operating Margin
Profit kept from selling products and services (higher is better)
-604.0%
✓ 적자
💡 적자 상태 — 수익을 내지 못하고 있습니다
Net Margin
Share of revenue left after taxes and interest are paid
-613.2%
✓ 적자
💡 적자 상태 — 수익을 내지 못하고 있습니다
Gross Margin
Profit after subtracting raw-material costs only (signals product competitiveness)
39.6%
✓ 평균
My positionMid-range
Low range Average High range
Biotechnology 초소형주 Median 53.4% · Bottom 44%
💡 제조업 30%, IT/소프트웨어 50% 이상이면 우수 (업종별 편차 큼)
ROE
Annual return earned on shareholders' equity (15%+ is strong)
-169.0%
✓ 적자
💡 적자 상태 — 수익을 내지 못하고 있습니다
ROA
Annual earnings relative to total company assets
-118.6%
✓ 적자
💡 적자 상태 — 수익을 내지 못하고 있습니다
ROIC
Return generated per dollar invested in the business
-151.9%
✓ 적자
💡 적자 상태 — 수익을 내지 못하고 있습니다
Financial health — Debt & liquidity burden
Debt-to-Equity (D/E)
Debt relative to equity (lower is healthier)
0.03
✓ Healthy debt
My positionMid-range
Low range Average High range
Biotechnology Median 0.05
💡 일반적으로 1.0 이하면 건전, 1.5까지는 무난 (금융·유틸·REIT는 구조적으로 높음)
Current Ratio
Liquid assets available to cover liabilities due within a year
3.34
✓ 양호
My positionMid-range
Low range Average High range
Biotechnology Median 5.75
💡 1.5~3.0 적정, 1.0 미만이면 단기 유동성 주의
Quick Ratio
Liquid assets excluding inventory, available for immediate use
2.85
✓ 양호
My positionMid-range
Low range Average High range
Biotechnology Median 5.47
💡 1.0 이상이면 안전, 0.5 미만이면 주의
* Ratings reflect relative position vs. peer-group distribution (same sector & size) plus absolute guards (loss & risk thresholds).

What's the outlook?

Positive Outlook
Price targets, growth, and valuation are favorable
애널리스트 목표가
$3.70
현재가 대비 +135.7%
💡 12개월 이내 도달을 전망하는 애널리스트 컨센서스 평균
내년 EPS 예상 성장률
+35.0%
💡 10% 이상이면 견조한 성장, 마이너스는 이익 감소 예상
5년 EPS 예상 연평균
+62.9%
💡 장기 성장 전망. 15% 이상이면 고성장 기업
⚠ 이 데이터는 애널리스트 추정치이며 실제 결과와 다를 수 있습니다. 투자 결정은 추가 검토와 함께 하세요.

Did earnings meet expectations?

High Earnings Volatility
Frequently misses analyst estimates
0
예상 상회
0
예상 부합
2
예상 하회
0%
상회 비율
-188.5%
평균 서프라이즈
2026.05.14
하회
-68.4%
2026.03.30
하회
실적 $-8.17 · 예상 $-2.00 -308.6%
💡 예상보다 높은 실적을 자주 내는 기업은 실적 신뢰도가 높다고 평가됩니다. 단, 애널리스트 기대치가 낮게 설정되었을 수도 있으니 절대 수치도 함께 봐야 합니다.

Is it growing?

Strong Growth
Above the industry average, both historically and going forward
Declining Growth EPS or revenue is declining — check for structural issues or economic sensitivity
🔮 How much will it grow? (analyst forecasts)
This Year's EPS Outlook
Projected EPS growth rate for this year
+71.9%
양호
My positionMid-range
Low range Average High range
초고성장주 초소형주 Median 50.1% · Top 27%
Next Year's EPS Outlook
Projected EPS growth rate for next year (analyst consensus)
+35.0%
양호
My positionMid-range
Low range Average High range
초고성장주 초소형주 Median 35.0% · Around average
5-Year EPS CAGR Outlook
Projected average annual EPS growth over the next 5 years
+62.9%
우수
My positionTop 25%
Low range Average High range
초고성장주 초소형주 Median 44.8% · Top 17%
📊 How much has it grown? (actual results)
Past 3-Year EPS
Actual average annual EPS growth over the past 3 years
+64.2%
우수
My positionTop 25%
Low range Average High range
초고성장주 초소형주 Median 27.5% · Top 20%
Past 5-Year EPS
Actual average annual EPS growth over the past 5 years
+37.7%
양호
My positionMid-range
Low range Average High range
초고성장주 초소형주 Median 20.7% · Top 32%
Past 5-Year Revenue
How much revenue grew over the past 5 years
-11.2%
매우 부진
My positionBottom 5%
Low range Average High range
초고성장주 초소형주 Median 47.0% · Bottom tier
⚡ Short-term momentum
QoQ Revenue
Revenue change from the previous quarter (short-term momentum)
-36.8%
부진
My positionBottom 25%
Low range Average High range
초고성장주 초소형주 Median 3.6% · Bottom 23%
* Forecast values are analyst consensus estimates. Ratings are determined by relative position vs. peer group of the same growth style and size.
New to investing terms? Look it up in the financial dictionary →

Has the stock risen over the long term?

Underperformed the market by 86%p over the past year
SXTP -70.0% · S&P 500 +16.0%
Excess return vs. market (price-based, ex-dividends)
1-year basis
vs S&P 500
-86.1%p
Significantly behind the market
vs Health Care (XLV)
-89.8%p
Significantly behind the sector average
Rank among peers
1-year return Lower-Mid (lower 32%) Based on 315 peers
Current position within 52-week range
Low (-28.7%p) High (-81.8%p)
Current price is 28.7% above the 52-week low and 81.8% below the 52-week high
Recent risk (last 120 trading days)
Max drawdown
-68.9%
Annualized volatility
126.5%

Technical Indicators

Bollinger Bands · MACD · RSI · Stochastics · Ichimoku 5-line · recent 136-day series

Price · Bollinger Bands · Ichimoku Cloud

  • close
  • BB Upper
  • BB Mid
  • BB Lower
  • Tenkan
  • Kijun
  • Cloud (SpanA/B)

Bollinger Bands are upper and lower channels showing the closing price range (20 days · 2σ). Touching the upper band = overheated; touching the lower band = oversold. Ichimoku Cloud shows trend direction and strength through colored areas. Prices above the cloud indicate an uptrend; prices below indicate a downtrend. About Bollinger Bands →

🔴
Current diagnosis · 2026-07-27
Downtrend zone

Current price $1.57 below the midline ($1.58). Normal downward flow. Inside the Ichimoku cloud (neutral).

MACD (12 · 26 · 9) Expand ▼

An indicator that uses the difference between the short-term EMA (12) and long-term EMA (26) to identify trend reversals. When MACD rises above the Signal line, it is a buy signal (golden cross); when it falls below, it is a sell signal (death cross). About MACD →

🔴
Current diagnosis · 2026-07-27
Bearish momentum holding

MACD -0.016 < Signal -0.011 in negative zone + Hist negative (-0.004). Weakness in progress.

RSI(14) · Stochastics %K(14) Expand ▼

RSI measures short-term buying and selling pressure on a scale of 0–100. 30 or below = oversold (a rebound may be possible); 70 or above = overbought (a pullback may be possible). Stoch %K similarly measures short-term momentum strength. RSI · Learn more about Stochastics →

🟢
Current diagnosis · 2026-07-27
Bullish zone

RSI 51.5 (above the neutral level of 50). Buying pressure leads, supporting a steady rise. Stoch %K is also 71.4.

※ "Current diagnosis" is an automated interpretation based on standard thresholds and is for reference only. Make your own comprehensive judgment before trading.

Is it attractive at this price?

Cheaper than peers in its industry
Cheap on Vs. Sales
💡 How to read this — Compare against peers in the same industry to see what the price is cheap or expensive relative to. Example: cheap vs. earnings = stock price is low relative to what the company earns; expensive vs. assets = stock price is high relative to assets on the balance sheet.
🧾 Vs. Sales Cheap
🧾 Vs. Sales
PSR Price-to-Sales Ratio
Market cap vs. revenue — lower is cheaper relative to sales
3.19x
✓ Very cheap
My positionTop 25%
Low range Average High range
Biotechnology 초소형주 median 11.24x · Top 25% — relatively cheap within the industry
💡 PSR 2 이하 저평가, 10 초과면 고평가 (고성장 기업일 때만 정당화)
Analyst target price (reference)
$3.70 vs. current price +135.7%
* Valuation is the stock's relative position within the industry peer group (same sector and market-cap range). Even when valuation looks attractive, check the 'Profitability' and 'Growth' sections too.
As of: Recent snapshot · Peer group: Biotechnology 초소형주

Who owns it?

Ownership flow is positive
Insider net buying +45.7% · Institutional net buying +8.3% · Short interest moderate 5.5% · Short interest up +0.9pp over last 89d
📈 Recent trading flow (6 months)
🧑‍💼 Insiders (executives & directors)
+45.7%
Insiders large net buying
🏦 Institutions (funds & investors)
+8.3%
Institutions net buying
💡 Net change over the past 6 months. Shows how much insiders and institutions increased or reduced their holdings, in %.
👥 Holdings composition
🏦 Institutions 7.3%
Retail-led
Healthcare 초소형주 Median 14.2%
🧑‍💼 Insiders 0.9%
Low, common among large-caps
Healthcare 초소형주 Median 16.1%
👤 Retail investors (estimated) 91.8%
Everyone excluding institutions and insiders
Institutions Insiders Retail (est.)
📉 Short-selling metrics
Short ratio
5.5%
Moderate
Healthcare 초소형주 Median 3.9%
Past 89 days 📈 +0.9%p increase
Short interest days to cover
1.7 days
Days needed to close short positions using average trading volume
🧮 Share count
Total shares outstanding 2.6M주
Float (tradable shares) 2.6M주
* Insider/institutional flows are based on net changes over the past 6 months. Trend is cumulative over the past 89 days.

How much does it pay in dividends?

This company does not pay a dividend

It may be a growth-focused firm reinvesting profits into expansion. Consider this growth-stock profile when investing.

Compare Industry Peers

💡 vs. sector average ▲ Favorable / ▼ Unfavorable (Lower PER and PBR are better; higher ROE and dividend yield are better)
Sorted by market cap, largest first
StockMarket CapPERPBRROEDividend YieldChange
SXTP SXTP This Stock
$4.2M- - -169.02% ▼- +6.1%
LLY
$1.13T43.1 ▼36.2 ▼107.64% ▲0.58% ▼+0.1%
JNJ
$640.9B30.8 ▼7.5 ▼25.74% ▲2.02% ▲+1.0%
ABBV
$453.9B126.7 ▼- 15221.82% ▲2.67% ▲-0.9%
UNH
$379.3B26.9 ▼3.9 ▼12.49% ▲2.16% ▲-0.7%
MRK
$323.0B36.8 ▼7.0 ▼18.97% ▲2.5% ▲-0.2%
Sector Avg-26.12.7-48.83%1.23%-
📊
See the market at a glance with a real-time dashboard Track premarket, regular, and after-hours quotes, screeners, and heatmaps on a single screen
→

Related News & Content

📖 Company overview
60 디그리스 파마슈티컬(SXTP) 뭐하는 회사일까? - 주가 전망·실적·시총·관련주·본사 총정리
$SXTP는 말라리아 예방약 Arakoda를 중심으로 감염성 질환 예방·치료제를 상용화하는 마이크로캡 스페셜티 제약사입니다.
📚 Related Investment Guides
미국주식 세금 총정리 2026 — 초보자를 위한 계산법과 절세 전략
2026년 미국주식 세금 총정리. 양도소득세 22% 계산법, 배당세 15% 원천징수, 손익통산, 절세 전략까지. 실제 금액 시뮬레이션과 세금 계산기로 내 세금을 직접 확인해보세요.

FAQ

What kind of company is 식스티 디그리즈 파마슈티컬스(SXTP)?

식스티 디그리즈 파마슈티컬스(SXTP) belongs to the Healthcare sector and operates in the Biotechnology industry.

What is the market cap of SXTP?

The market cap of SXTP is approximately $4M, ranking 5,711 within its sector.

What is the 52-week high and low for SXTP?

SXTP has recorded a 52-week high of $8.62 and a low of $1.22.

시황 · 실적발표 · 매수매도 신호, 가장 먼저 받아보세요 🔔 구독

면책조항: 본 콘텐츠는 참고 자료이며 투자 권유가 아닙니다. 모든 투자의 책임은 투자자 본인에게 있습니다.